Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, Katelaris C, Sussman G, Keith PK, Yang W, Hébert J, Hanzlikova J, Staubach-Renz P, Martinez-Saguer I, Magerl M, Aygören-Pürsün E, Farkas H, Reshef A, Kivity S, Neri S, Crisan I, Caballero T, Baeza ML, Hernandez MD, Li H, Lumry W, Bernstein JA, Hussain I, Anderson J, Schwartz LB, Jacobs J, Manning M, Levy D, Riedl M, Christiansen S, Feuersenger H, Pragst I, Mycroft S, Pawaskar D, Jacobs I; COMPACT Investigators. Craig T, et al. Among authors: pragst i. J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):1793-1802.e2. doi: 10.1016/j.jaip.2019.01.054. Epub 2019 Feb 15. J Allergy Clin Immunol Pract. 2019. PMID: 30772477 Free article. Clinical Trial.
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H, Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J, Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz LB, Caballero T, Yang W, Crisan I, Hernandez MD, Hussain I, Tarzi M, Ritchie B, Králíčková P, Guilarte M, Rehman SM, Banerji A, Gower RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Machnig T, Pawaskar D, Pragst I, Zuraw BL; COMPACT Investigators. Longhurst H, et al. Among authors: pragst i. N Engl J Med. 2017 Mar 23;376(12):1131-1140. doi: 10.1056/NEJMoa1613627. N Engl J Med. 2017. PMID: 28328347 Free article. Clinical Trial.
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
Zhang Y, Tortorici MA, Pawaskar D, Pragst I, Machnig T, Hutmacher M, Zuraw B, Cicardi M, Craig T, Longhurst H, Sidhu J. Zhang Y, et al. Among authors: pragst i. CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):158-165. doi: 10.1002/psp4.12271. Epub 2018 Jan 9. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 29316335 Free PMC article.
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ. Lumry WR, et al. Among authors: pragst i. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31. J Allergy Clin Immunol Pract. 2018. PMID: 29391286 Free article. Clinical Trial.
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.
Li HH, Zuraw B, Longhurst HJ, Cicardi M, Bork K, Baker J, Lumry W, Bernstein J, Manning M, Levy D, Riedl MA, Feuersenger H, Prusty S, Pragst I, Machnig T, Craig T; COMPACT Investigators. Li HH, et al. Among authors: pragst i. Allergy Asthma Clin Immunol. 2019 Aug 28;15:49. doi: 10.1186/s13223-019-0362-1. eCollection 2019. Allergy Asthma Clin Immunol. 2019. PMID: 31485239 Free PMC article.
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
Levy DS, Farkas H, Riedl MA, Hsu FI, Brooks JP, Cicardi M, Feuersenger H, Pragst I, Reshef A. Levy DS, et al. Among authors: pragst i. Allergy Asthma Clin Immunol. 2020 Feb 4;16:8. doi: 10.1186/s13223-020-0409-3. eCollection 2020. Allergy Asthma Clin Immunol. 2020. PMID: 32042283 Free PMC article.
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
Bernstein JA, Schwartz L, Yang W, Baker J, Anderson J, Farkas H, Aygören-Pürsün E, Bygum A, Jacobs I, Feuersenger H, Pragst I, Riedl MA. Bernstein JA, et al. Among authors: pragst i. Ann Allergy Asthma Immunol. 2020 Sep;125(3):334-340.e1. doi: 10.1016/j.anai.2020.05.015. Epub 2020 May 20. Ann Allergy Asthma Immunol. 2020. PMID: 32445670 Free article. Clinical Trial.
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Levy D, Caballero T, Hussain I, Reshef A, Anderson J, Baker J, Schwartz LB, Cicardi M, Prusty S, Feuersenger H, Pragst I, Manning ME. Levy D, et al. Among authors: pragst i. Pediatr Allergy Immunol Pulmonol. 2020 Sep 1;33(3):136-141. doi: 10.1089/ped.2020.1143. Epub 2020 Sep 16. Pediatr Allergy Immunol Pulmonol. 2020. PMID: 32953229 Free PMC article. Clinical Trial.
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Pawaskar D, Jacobs I, Pragst I, Doyle MK. Craig T, et al. Among authors: pragst i. Lancet. 2022 Mar 5;399(10328):945-955. doi: 10.1016/S0140-6736(21)02225-X. Epub 2022 Feb 24. Lancet. 2022. PMID: 35219377
44 results